Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPharmacological TreatmentsType 2 Diabetes (T2D)Complications
Research Summary
Analyzed using Evidence Intelligence™
Tadalafil may shift neurodegeneration biomarkers in type 2 diabetes
Last updated June 15, 2026
Key finding
Amyloid-β 40 period adjusted mean difference tadalafil vs placebo -22.0 (-36.2; -8.05), p=0.0072
This small trial analysis tested daily tadalafil in people with type 2 diabetes. Tadalafil lowered some blood biomarkers related to amyloid metabolism and astroglial activation, but it did not change several other brain-related biomarkers.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Low
Study type
Randomized controlled trial
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This small trial analysis tested daily tadalafil in people with type 2 diabetes. Tadalafil lowered some blood biomarkers related to amyloid metabolism and astroglial activation, but it did not change several other brain-related biomarkers.
Clinical relevance
People with type 2 diabetes have higher dementia risk, so understanding how diabetes medications affect brain-related blood biomarkers may be useful. This study suggests tadalafil can alter some biomarkers used in neurodegeneration research. However, the analysis did not measure cognitive outcomes and was too small to show whether these biomarker changes translate into clinical benefit.
Keep in mind
Very small per-protocol sample size of 15 participants. Post-hoc biomarker analysis, not powered for these outcomes. No cognitive performance measurements before and after treatment. Some pTau217 measurements were below quantification limits.
Main Effects
↓ Plasma amyloid-β 40 and amyloid-β 42 compared with placebo
↓ Plasma GFAP compared with placebo
→ No clear effect on amyloid-β 42/40 ratio, pTau217, NfL, or GDF-15
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tadalafil and Amyloid-β 40, Amyloid-β 42, Amyloid-β 42/40 ratio, and 6 more.
This study contributes evidence to
Primary intervention
Tadalafil
Primary outcomes
- Amyloid-β 40
- Amyloid-β 42
- Amyloid-β 42/40 ratio
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
9
Evidence pairs
9
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 56
3
Related topics
9
Evidence pairs
465
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 9 evidence relationships
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
DPP-4 Inhibitors and HbA1c
Related evidence
Evidence relationship
DPP-4 Inhibitors and Fasting Glucose
Save evidence
Evidence relationship
DPP-4 Inhibitors and Inflammatory Markers
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerGlial fibrillary acidic protein
Tadalafil → Glial fibrillary acidic protein
Tadalafil → Glial fibrillary acidic protein
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerGrowth differentiation factor 15
Tadalafil → Growth differentiation factor 15
Tadalafil → Growth differentiation factor 15
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerNeurofilament light protein
Tadalafil → Neurofilament light protein
Tadalafil → Neurofilament light protein
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Keep in Mind
- Very small per-protocol sample size of 15 participants. Post-hoc biomarker analysis, not powered for these outcomes. No cognitive performance measurements before and after treatment. Some pTau217 measurements were below quantification limits.
Between the Lines
- Very small per-protocol sample size of 15 participants. Post-hoc biomarker analysis, not powered for these outcomes. No cognitive performance measurements before and after treatment. Some pTau217 measurements were below quantification limits.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and Neurodegeneration Biomarkers, DPP-4 Inhibitors and Neurodegeneration Biomarkers.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
DPP-4 Inhibitors Evidence Hub
All studies on DPP-4 Inhibitors
1 studies
intervention_hubContributes to DPP-4 Inhibitors evidence base.
Neurodegeneration Biomarkers Evidence Hub
All studies measuring Neurodegeneration Biomarkers
1 studies
outcome_hubMeasures Neurodegeneration Biomarkers as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tadalafil and Amyloid-β 40
Intervention: TadalafilOutcome: Amyloid-β 40
1 results
All studies on Tadalafil and Amyloid-β 42
Intervention: TadalafilOutcome: Amyloid-β 42
1 results
All studies on Tadalafil
Intervention: Tadalafil
1 results
All studies measuring Amyloid-β 40
Outcome: Amyloid-β 40
1 results
All studies measuring Amyloid-β 42
Outcome: Amyloid-β 42
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does DPP-4 Inhibitors improve HbA1c?
Strong Evidence
DPP-4 Inhibitors appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors improve fasting glucose?
Moderate Evidence
DPP-4 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does DPP-4 Inhibitors improve inflammatory markers?
Emerging Evidence
DPP-4 Inhibitors may improve Inflammatory Markers.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Growth differentiation factor 15
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does DPP-4 Inhibitors improve neurodegeneration biomarkers?
Emerging Evidence
Current evidence does not show a clear benefit of DPP-4 Inhibitors for Neurodegeneration Biomarkers.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Amyloid-β 42/40 ratio
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
- 2
Neurofilament light protein
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
- 3
Phosphorylated tau217
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Natural products may improve glycemic control in type 2 diabetesHRS-7535 improves glycemic control in adults with type 2 diabetesNewer diabetes drugs show stronger weight and blood sugar benefits in prediabetesVitamin D supplementation shows little effect on glycemic control in type 2 diabetesAdding medications improves blood sugar control in diabetes patients.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.